FREMONT, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today reported financial results for the second quarter ended June 30, 2025.
GARDENA, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polar Power, Inc. (“Polar Power” or the “Company”) (NASDAQ: POLA), a global provider of prime, backup, and solar hybrid DC power solutions, reports its financial results for the three months ended June 30, 2025.
HOBOKEN, N.J., Aug. 14, 2025 /PRNewswire/ -- Quantum Computing Inc. ("QCi" or the "Company") (Nasdaq: QUBT), an innovative, integrated photonics and quantum optics technology company, today...
- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) -
- Cash, cash equivalents, and marketable securities of $296.3...
TORRANCE, Calif., Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...
Jafurah Midstream Gas Company secures significant foreign direct investment, together with agreement to lease and leaseback development and usage rights for Aramco's Jafurah midstream...
Jafurah Midstream Gas Company secures significant foreign direct investment, together with agreement to lease and leaseback development and usage rights for Aramco's Jafurah midstream...
Unaudited consolidated net profit of the INVL Baltic Farmland amounted to EUR 244,000 for 6 months of 2025 and the revenue was EUR 427,000 (for 6 months of 2024 consolidated net profit was EUR 226,000 and revenue was EUR 402,000).
RENO, Nev., Aug. 14, 2025 (GLOBE NEWSWIRE) -- GlobalTech Corporation (OTCID:GTLK) (“GlobalTech” or the “Company”), a technology holding company specializing in artificial intelligence (AI) and big data solutions, today announced its financial results for the second quarter ended June 30, 2025.
Company exits low-margin product lines, invests in higher-margin, innovative CEA-informed, better-for-you shelf-stable products, and expands global reach
Adjusted EBITDA grew 21% in Q2 and 29% year-to-date Cash from operations grew 83% in Q2 and 147% year-to-dateMade principal repayments on the Company's...
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –